Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Cash from Operations (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Cash from Operations for 15 consecutive years, with 844000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations fell 8.07% year-over-year to 844000.0, compared with a TTM value of 2909000.0 through Sep 2025, up 75.27%, and an annual FY2024 reading of 4971000.0, up 83.51% over the prior year.
  • Cash from Operations was 844000.0 for Q3 2025 at Alaunos Therapeutics, down from 701000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 592000.0 in Q4 2024 and bottomed at 21452000.0 in Q2 2021.
  • Average Cash from Operations over 5 years is 6743684.21, with a median of 7002000.0 recorded in 2023.
  • The sharpest move saw Cash from Operations crashed 54.58% in 2021, then soared 91.98% in 2024.
  • Year by year, Cash from Operations stood at 15126000.0 in 2021, then soared by 52.86% to 7130000.0 in 2022, then decreased by 3.58% to 7385000.0 in 2023, then skyrocketed by 91.98% to 592000.0 in 2024, then crashed by 42.57% to 844000.0 in 2025.
  • Business Quant data shows Cash from Operations for TCRT at 844000.0 in Q3 2025, 701000.0 in Q2 2025, and 772000.0 in Q1 2025.